title: Metoclopramide for preventing pneumonia in critically ill patients receiving enteral tube feeding: a randomized controlled trial.
abstract: OBJECTIVE
  To determine whether metoclopramide prevents nosocomial pneumonia in intensive care unit (ICU) patients receiving enteral feeding by a nasogastric tube.
  
  
  METHODS
  Prospective, randomized, controlled trial.
  
  
  METHODS
  ICU of a university hospital.
  
  
  METHODS
  A total of 305 consecutive patients requiring placement of a nasogastric tube for >24 hrs.
  
  
  METHODS
  Patients were randomized to receive either 10 mg of metoclopramide or placebo at 8-hr intervals through the nasogastric tube.
  
  
  RESULTS
  A total of 174 patients received placebo and 131 received metoclopramide. Baseline characteristics in the two treatment groups were comparable. Of the 305 patients, 46 developed nosocomial pneumonia, which was 24 patients (13.7%) in the placebo group and 22 (16.8%) in the metoclopramide group (p > .05). Patients in the placebo group developed pneumonia earlier than patients receiving metoclopramide (4.46+/-1.72 days [mean +/- SD[rsqb] after ICU admission compared with 5.95+/-1.78 days; p = .006). Subgroup analysis showed that metoclopramide did not reduce the frequency rate of pneumonia in patients with tracheal intubation (19 [25.3%] of 75 patients receiving metoclopramide vs. 21 [21.2%] of 99 patients receiving placebo) or those receiving mechanical ventilation (17 [25.6%] of 58 patients receiving metoclopramide vs. 20 [29.3%] of 78 patients receiving placebo). The mortality rate also did not differ in the two treatments groups (56% in the metoclopramide group vs. 53% in the placebo group; p > .05).
  
  
  CONCLUSIONS
  Although metoclopramide delayed the development of nosocomial pneumonia, it did not decrease its frequency rate and had no effect on the mortality rate in critically ill patients receiving nasogastric enteral feeding.
authors.affiliation: Department of Medicine, King Edward VII Memorial Hospital, Parel, Mumbai, India.
authors.forename: D R
authors.initials: DR
authors.lastname: Yavagal
authors.forename: D R
authors.initials: DR
authors.lastname: Karnad
authors.forename: J L
authors.initials: JL
authors.lastname: Oak
mesh_terms: D000932:Antiemetics / Q000008:administration & dosage* / Q000009:adverse effects; D003422:Critical Care; D003428:Cross Infection / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004750:Enteral Nutrition; D006801:Humans; D007262:Infusions, Intravenous; D008787:Metoclopramide / Q000008:administration & dosage* / Q000009:adverse effects; D011015:Pneumonia, Aspiration / Q000517:prevention & control*; D018410:Pneumonia, Bacterial / Q000517:prevention & control*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000932:Antiemetics; D008787:Metoclopramide